News Catalent acquires gene therapy specialist Paragon for $1.2bn Drug delivery technology provider Catalent is to acquire gene therapy company Paragon for $1.2 billion.
Patients Delivering the right behavioural ingredients for the moment,... Lirio's Dr Amy Bucher discusses the risks of the declining trust in healthcare institutions from a behavioural science perspective.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
